title: Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?
abstract: OBJECTIVE
  It remains uncertain whether current smoking influences outcome in patients with acute ischaemic stroke.
  
  
  OBJECTIVE
  To evaluate the effect of current smoking in routinely tissue plasminogen activator (tPA)-treated stroke patients on the 3-month functional outcome and the occurrence of symptomatic intracerebral hemorrhage (ICH).
  
  
  METHODS
  We analyzed data from a single stroke care unit registry of 345 consecutive patients with ischaemic stroke, treated with tPA. Logistic regression models were used to assess if smoking was independently associated with 3-months good outcome defined as a modified Rankin Scale score of < or =2, and the occurrence of symptomatic ICH.
  
  
  RESULTS
  In the multivariable models, smoking was not associated with a good outcome or a decreased risk of symptomatic ICH.
  
  
  CONCLUSIONS
  Current smoking did not affect functional outcome at 3 months or the risk of symptomatic ICH in patients routinely treated with tPA for ischaemic stroke.
authors.affiliation: Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands. m.j.h.aries@neuro.umcg.nl
authors.forename: M J H
authors.initials: MJ
authors.lastname: Aries
authors.forename: M
authors.initials: M
authors.lastname: Uyttenboogaart
authors.forename: M W
authors.initials: MW
authors.lastname: Koch
authors.forename: M
authors.initials: M
authors.lastname: Langedijk
authors.forename: P C
authors.initials: PC
authors.lastname: Vroomen
authors.forename: G J
authors.initials: GJ
authors.lastname: Luijckx
authors.forename: J
authors.initials: J
authors.lastname: De Keyser
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012907:Smoking / Q000009:adverse effects*; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator